ALPS Medical Breakthroughs ETF SBIO
53.00 USD -2.81 (-5.04%)
At closeNov 5, 2026, 4:04 PM EST
52.83 -0.17 -0.31%
After hours · Nov 5, 4:04 PM ET
53.09 Day range 55.09
43.10 52-week range 70.85
- YTD
- +3.47%
- 1 year
- +21.16%
- Market cap
- 186.95M
- YTD return
- +3.47%
- 1-year return
- +21.16%
- Volume
- 19.60K
- Avg volume
- 38.46K
- Open
- 55.96
- Previous close
- 55.81
- Day's range
- 53.09 – 55.09
- 52-week range
- 43.10 – 70.85
3M -14.01 (-20.85%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 38.30
- 200-day average
- 35.94
About ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
News
Biotech ETF SBIO Can Get Its Groove Back 
SBIO: Promising Pipelines, Insufficient Return Potential 
SBIO: Big Pharma Needs What This Fund Owns 
SBIO ETF Rallies on Clinical Trial Wins & M&A Demand 
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)? 
Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript 
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record 
Risk-Wary Family Offices Double Down on Infrastructure 
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals 
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Your note
Sign in to keep a note on SBIO — it syncs with the Stock Master app.